L
Linda L. Chang
Researcher at Merck & Co.
Publications - 39
Citations - 1013
Linda L. Chang is an academic researcher from Merck & Co.. The author has contributed to research in topics: Angiotensin II & Angiotensin II receptor type 1. The author has an hindex of 19, co-authored 39 publications receiving 997 citations.
Papers
More filters
Journal ArticleDOI
Substituted Imidazoles as Glucagon Receptor Antagonists
Linda L. Chang,Kelly L. Sidler,Margaret A. Cascieri,Stephen E. de Laszlo,Greg E. Koch,Bing Li,Malcolm MacCoss,Nathan B. Mantlo,Stephen J. O'Keefe,Margaret Pang,Anna M. Rolando,William K. Hagmann +11 more
TL;DR: A modestly active, nonselective triarylimidazole lead was optimized for binding affinity with the human glucagon receptor and the identification of a 2- and/or 4-alkyl or alkyloxy substituent on the imidazoles C4-aryl group as a structural determinant for significant enhancement in binding with the glucagon receptors.
Patent
Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists
Linda L. Chang,Wallace T. Ashton,Malcolm MacCoss,Prasun K. Chakravarty,William J. Greenlee,Arthur A. Patchett,Thomas F. Walsh +6 more
TL;DR: In this paper, the authors disclosed new substituted triazolinone, triazolethione, and triazolineimine compounds which are useful as angiotensin II antagonists.
Journal ArticleDOI
The discovery of sulfonylated dipeptides as Potent VLA-4 antagonists
William K. Hagmann,Philippe L. Durette,Thomas J. Lanza,Nancy J. Kevin,Stephen E. de Laszlo,Ihor E. Kopka,David N. Young,Plato A. Magriotis,Bing Li,Linus S. Lin,Ginger X. Yang,Theodore M. Kamenecka,Linda L. Chang,Jonathan E. Wilson,Malcolm MacCoss,Sander G. Mills,Gail Van Riper,Ermengilda McCauley,Linda A. Egger,Usha Kidambi,Kathryn A. Lyons,Stella H. Vincent,Ralph A. Stearns,Adria Colletti,Johannes Teffera,Sharon Tong,Judy Fenyk-Melody,Karen Owens,Dorothy Levorse,Philip Kim,John A. Schmidt,Richard A. Mumford +31 more
TL;DR: SAR and pharmacokinetic characterization of this series of sulfonylated dipeptide inhibitors with structural components that when combined in a single hybrid molecule gave a sub-nanomolar inhibitor as a lead for medicinal chemistry are presented.
Patent
Substituted triazoles as angiotensin ii antagonists
Wallace T. Ashton,Linda L. Chang,Christine L. Cantone,Malcolm MacCoss,Prasun K. Chakravarty,Arthur A. Patchett,Thomas F. Walsh,William J. Greenlee +7 more
TL;DR: In this paper, the substituted triazoles of the formula (I) were used as angiotensin II antagonists, which are useful as angio-nocaine antagonists.
Journal ArticleDOI
Nonpeptide angiotensin II antagonists derived from 4H-1,2,4-triazoles and 3H-imidazo[1,2-b][1,2,4]triazoles.
Wallace T. Ashton,Christine L. Cantone,Linda L. Chang,Steven M. Hutchins,Robert A. Strelitz,M. Maccoss,R. S. L. Chang,Victor J. Lotti,Kristie A. Faust,Tsing-Bau Chen +9 more
TL;DR: Most potent among the bicyclic derivatives was 2-n-butyl-5,6-dimethyl-3-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]meth yl]- 3H-imidazo[1,2-b][1, 2,4]triazole (93, IC50 7.8 nM).